Shares of MELA Sciences (MELA) are on watch Monday after a NY Times article highlights the...

|By:, SA News Editor

Shares of MELA Sciences (MELA) are on watch Monday after a NY Times article highlights the debate around MelaFind, the company's FDA approved melanoma-finding computer vision device which uses algorithms to pick out irregularities in pigmented skin legions. "My concern with MelaFind is that it just says everything is positive," one biostatistician who sat on the FDA review panel which evaluated the device says. "It will err on the side of caution," counters the company's director of commercialization. It will be interesting to see if the system can gain traction in what is quickly becoming a tough market for medical devices (I, II).